Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33800983)
Watch
English
Chemotherapy for advanced hormone refractory prostate cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
review article
1 reference
stated in
Europe PubMed Central
title
Chemotherapy for advanced hormone refractory prostate cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
main subject
chemotherapy
1 reference
based on heuristic
inferred from title
prostate cancer
1 reference
based on heuristic
inferred from title
author name string
Petrylak DP
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
language of work or name
English
0 references
publication date
1 December 1999
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
published in
Urology
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
volume
54
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
page(s)
30-35
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
issue
6A Suppl
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
cites work
Cancer statistics, 1999.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900452-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0090-4295(99)00452-5
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
PubMed ID
10606282
1 reference
stated in
Europe PubMed Central
PubMed ID
10606282
retrieved
29 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
